Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Immunitor** is a non-specific name used for a family of orally administered therapeutic vaccine products developed by Immunitor. In the provided context, it refers not to one single molecular entity but to several distinct oral tableted biologic immunotherapies, including V-1 for HIV/AIDS, V-5 for hepatitis B, hepatitis C, tuberculosis, and hepatocellular carcinoma-related development, and V7 for tuberculosis. These products are described as oral therapeutic vaccines based on inactivated or pooled pathogen-derived antigens, designed to stimulate mucosal and innate immune responses rather than acting through a single well-defined receptor target. Because the exact active composition, pathogen content, and indication vary by product, \"Immunitor\" should be treated as an umbrella product name rather than a uniquely identifiable drug substance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Immunitor.